AgomAb Therapeutics
(Incorporated in Belgium) We are a Phase 2 clinical biotech focused on discovering and/or developing new treatments for diseases in the immunology and inflammatory category. Our leading product candidates are: *Ontunisertib (AGMB-129) – An oral treatment for Crohn’s disease with fibrostenosis, and *AGMB-447 – An inhaled treatment for idiopathic pulmonary fibrosis (IPF). Our product candidates […]
January 16, 2026 Read More